[{"address1": "3 More London Riverside", "city": "London", "zip": "SE1 2RE", "country": "United Kingdom", "phone": "44 20 3283 4200", "website": "https://www.veronapharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.", "fullTimeEmployees": 209, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Scott Zaccardelli Pharm.D.", "age": 60, "title": "President, CEO & Executive Director", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 1366973, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark W. Hahn CPA", "age": 61, "title": "Chief Financial Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 915915, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Fisher", "age": 54, "title": "General Counsel", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 596932, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kathleen A. Rickard M.D.", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 726000, "exercisedValue": 0, "unexercisedValue": 3341500}, {"maxAge": 1, "name": "Ms. Victoria  Stewart", "title": "Senior Director of Investor Relations & Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Casbon", "title": "VP of Sales, Marketing & Training", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ostra  Jewell", "title": "Senior Vice President of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tara  Rheault M.P.H., Ph.D.", "age": 48, "title": "Chief Development Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Martin", "title": "Chief Commercial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Diaz", "title": "Chief Regulatory Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.veronapharma.com/s/AIM26.asp", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 106.91, "open": 106.85, "dayLow": 106.91, "dayHigh": 106.91, "regularMarketPreviousClose": 106.91, "regularMarketOpen": 106.85, "regularMarketDayLow": 106.91, "regularMarketDayHigh": 106.91, "payoutRatio": 0.0, "beta": 0.052, "forwardPE": -381.82144, "volume": 1871051, "regularMarketVolume": 1871051, "averageVolume": 1688607, "averageVolume10days": 1582602, "averageDailyVolume10Day": 1582602, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 9085092864, "fiftyTwoWeekLow": 31.6, "fiftyTwoWeekHigh": 106.93, "allTimeHigh": 106.93, "allTimeLow": 2.01, "priceToSalesTrailing12Months": 40.98421, "fiftyDayAverage": 105.9476, "twoHundredDayAverage": 79.83633, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 73524756480, "profitMargins": -0.36625, "floatShares": 564820417, "sharesOutstanding": 84978881, "sharesShort": 2026271, "sharesShortPriorMonth": 2081728, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.0234, "heldPercentInsiders": 0.04887, "heldPercentInstitutions": 0.92227, "shortRatio": 1.56, "shortPercentOfFloat": 0.024400001, "impliedSharesOutstanding": 84978896, "bookValue": 3.236, "priceToBook": 33.0377, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -81187000, "trailingEps": -1.04, "forwardEps": -0.28, "enterpriseToRevenue": 331.681, "enterpriseToEbitda": -1394.178, "52WeekChange": 2.0571918, "SandP52WeekChange": 0.16625166, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "VRNA", "underlyingSymbol": "VRNA", "shortName": "Verona Pharma plc", "longName": "Verona Pharma plc", "firstTradeDateEpochUtc": 1493299800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f8092d8b-294d-3651-a8fa-78639155df65", "messageBoardId": "finmb_25217246", "gmtOffSetMilliseconds": -14400000, "currentPrice": 106.91, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 438016000, "totalCashPerShare": 0.635, "ebitda": -52737000, "totalDebt": 244374000, "quickRatio": 10.245, "currentRatio": 10.712, "totalRevenue": 221672992, "debtToEquity": 87.818, "revenuePerShare": 2.647, "returnOnAssets": -0.06684, "returnOnEquity": -0.36361998, "grossProfits": 210928000, "freeCashflow": -57391248, "operatingCashflow": -72491000, "grossMargins": 0.95153, "ebitdaMargins": -0.2379, "operatingMargins": 0.129, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-10-25"}]